Android app Apple app link

AbbVie (NYSE:ABBV) Reports ELAHERE Success in Phase 3 Trials for Platinum-Resistant Ovarian Cancer

By Yahoo! Finance   |   1 month ago
AbbVie (NYSE:ABBV) Reports ELAHERE Success in Phase 3 Trials for Platinum-Resistant Ovarian Cancer

AbbVie's success in the MIRASOL trial of ELAHERE for ovarian cancer led to a 23% rise in its share price. Despite mixed financial performance, the company's advancements in oncology and strong shareholder returns show promise for investors.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.